Your email has been successfully added to our mailing list.

×
0.00446428571428562 0.00446428571428562 0 0.00446428571428562 -0.00446428571428582 0.00446428571428562 0.00446428571428562 0.00446428571428562
Stock impact report

CORRECTING and REPLACING -- Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer

Celsion Corporation (CLSN) 
Last celsion corporation earnings: 11/14 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.celsion.com/investor-relations
Company Research Source: GlobeNewswire
 Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed Stage III and IV Ovarian Cancer GEN-1 Immunotherapy to Enter Phase I/II Clinical Study in the First Half of 2018 Following a Phase IB Trial Demonstrating 100% Disease Control, 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated LAWRENCEVILLE, N.J., Nov. 13, 2017 (GLOBE NEWSWIRE) -- In a press release issued earlier today by Celsion Corporation (NASDAQ:CLSN), please note multiple changes were made to the fourth bullet point of the release. The corrected release follows: Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced the submission of its Phase I/II clinical trial protocol to the U.S. Food and Drug Administration (FDA) for GEN-1, the Company’s DNA-based immunotherapy for the localized treatment of ovarian cancer.  The protocol, developed in conjunction with guidance from the Company’s Medical Advisory Board, is designed w Show less Read more
Impact Snapshot
Event Time:
CLSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CLSN alerts
Opt-in for
CLSN alerts

from News Quantified
Opt-in for
CLSN alerts

from News Quantified